By: IPP Bureau
Last updated : April 07, 2026 1:28 pm
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Thyrocare Technologies has launched its ‘Bharat Aarogyam Score’, one of India’s largest real-world preventive health analyses, drawing insights from more than 93 lakh health checkups conducted between 2023 and 2025.
The report, unveiled on World Health Day, paints a concerning picture of India’s silent disease burden, revealing that over 90% of individuals show early signs of at least one health condition.
The large-scale analysis evaluated 10 major health condition groups, including diabetes, heart health, liver and kidney function, thyroid imbalance, low hemoglobin, vitamin deficiencies, and cancer risk indicators. Among the most striking findings, more than 8 in 10 people were at risk for at least two conditions, over 6 in 10 for at least three, and nearly 2 in 10 for five or more conditions.
A key insight from the report is the early onset of non-communicable disease risks, especially heart disease and diabetes. The data shows a sharp rise in both conditions in the 21–40 age group, with heart risk doubling by the 30s and diabetes risk more than doubling by the 40s. Kidney-related risks rise sharply after 60, while thyroid imbalances show a steady increase across all age groups.
Gender trends in the analysis also reveal notable differences. Low hemoglobin prevalence is nearly 2.5 times higher in women, while men show 1.5 times higher liver marker abnormalities. Interestingly, thyroid imbalance was only 1.4 times higher in women, challenging common assumptions, while Vitamin B12 deficiency was 1.4 times higher in men.
Commenting on the launch, Rahul Guha, MD & CEO, Thyrocare Technologies Ltd, said, “As GLP-1-based medicines become more widely used in India for weight management and diabetes, it’s important to accompany this trend with reliable diagnostic support. These therapies are powerful and effective when used responsibly, but they work best when combined with consistent monitoring. With this package, our goal is to make that process easier and more accessible for people across the country.”
Dr. Shehla Shaikh, MD (General Medicine), DM (Endocrinology), consulting endocrinologist at leading hospitals, emphasised, “As obesity emerges as a global health challenge, it is essential to pair weight-management GLP-1 therapy with structured medical monitoring, beginning with baseline screening and continuing with periodic reviews."